Abstract
Antibiotics resistance poses catastrophic threat to global public health. Novel insights into the underlying mechanisms of action will inspire better measures to control drug resistance. Fluoroquinolones are potent and widely prescribed broad-spectrum antibiotics. Bacterial protein degradation pathways represent novel druggable target for the development of new classes of antibiotics. Mycobacteria proteasome accessory factor C (pafC), a component of bacterial proteasome, is involved in fluoroquinolones resistance. PafC deletion mutants are hypersensitive to fluoroquinolones, including moxifloxacin, norfloxacin, ofloxacin, ciprofloxacin, but not to other antibiotics such as isoniazid, rifampicin, spectinomycin, chloramphenicol, capreomycin. This phenotype can be restored by complementation. The pafC mutant is hypersensitive to H2O2 exposure. The iron chelator (bipyridyl) and a hydroxyl radical scavenger (thiourea) can abolish the difference. The finding that pafC is a novel intrinsic selective resistance gene provided new evidence for the bacterial protein degradation pathway as druggable target for the development of new class of antibiotics.
Similar content being viewed by others
Introduction
Tuberculosis, caused by Mycobacterium tuberculosis, remains a leading cause of mortality and morbidity worldwide1. One-third of the global population is latently infected with M. tuberculosis and millions die annually due to active tuberculosis2. Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) have worsened this scenario3,4. M. tuberculosis is intrinsically tolerant to most antibiotics largely due to the imperviousness of its unusual mycolic acid-containing cell wall5 to most chemotherapeutics6 and a wealth of efflux pumps7. Some genes involved in metabolism also can mediate intrinsic resistance in mycobacterium. The inactivation of asparagine synthetase AsnB, an asparagine biosynthetic enzyme catalyzing the transfer of the γ-amino residue of glutamine to the carboxyl residue of aspartate, dramatically sensitized M. smegmatis to multiple antibiotics, including rifampin, erythromycin, novobiocin and fusidic acid8. It is imperative to find novel therapeutic targets or new effective antibiotics against tuberculosis.
Fluoroquinolones are important second-line drugs for the treatment of tuberculosis and the new generation of fluoroquinolones (moxifloxacin) is becoming an important antituberculosis agent as both a first-line therapeutic9 and a second-line treatment for multidrug-resistant tuberculosis10,11. With the widespread administration of quinolones, the incidence of fluoroquinolone-resistant M. tuberculosis kept rising12. M. tuberculosis DNA gyrase, encoded by gyrA and gyrB, is well estabilished quinolone target13. Mutations within the highly conserved region, the so-called quinolone resistance-determining region (QRDR) of gyrA/gyrB, have been reported to be responsible for ≥70% of FQ resistance in clinical M. tuberculosis isolates14.
Intracellular protein degradation is essential for almost all organisms. For most organisms, there are two canonical intracellular degradation ways targeting unwanted proteins, namely proteolysis in lysosome and an ubiquitin-dependent process. While in M. tuberculosis, a prokaryotic ubiquitin-like protein (Pup) can tag the unwanted proteins, which is catalyzed by proteasomal accessory factor A (pafA) to form an isopeptide bonds between the γ carboxyl group of Pup glutamate and the side chain amine of lysine of protein substrate15. The Pup-proteasome system (pps) is essential for the virulence and persistence of pathogen within host. The widespread of PPS-system among non-pathogens implicates additional roles in cellular processes, which is reinforced by the supportive role of proteasome-mediated amino acid recycling for the survival of mycobacteria under nutrient limitation16. The essentiality of the M. tuberculosis proteasome pathway enabled it ideal drug target17. pafA is cotranscribed with two genes, namely pafB and pafC, which are dispensable for the function of M. tuberculosis proteasome15,18. However, the detailed function of pafC remains elusive.
In this study, we characterized the function of pafC. Using the M. smegmatis pafC mutant we isolated, we found that pafC might play a role in the intrinsic resistance to fluoroquinolones. The pafC deficiency potentiated the lethality of fluoroquinolones, such as moxifloxacin, norfloxacin, ofloxacin, ciprofloxacin and environmental stress, such as hydrogen peroxide. Both an iron chelator (bipyridyl) and a hydroxyl radical scavenger (thiourea) can lower the moxifloxacin lethality, while moxifloxacin at low concentration did not have such effect. In brief, we firstly characterized the Proteasome Accessory Factor C (pafC) and found its potential role in the intrinsic resistance of mycobacterium to fluoroquinolones. Reactive oxygen species were proposed to mediate the function of pafC.
Results
Isolation and characterization of hypersensitive mutant M371 for fluoroquinolones
To identify mycobacteria genes involved in the intrinsic resistance to fluoroquinolones, we screened fluoroquinolones sensitive isolates using sublethal concentrations of moxifloxacin and obtained one mutant (named M371) hypersensitive to moxifloxacin from the constructed transposon insertion mutant library of M. smegmatis mc2155. No evident growth defect can be spotted when mutant cell was grown in 7H9 medium supplemented with 0.05% Tween80 and 0.2% glycerinum (Fig. 1). The mutant of M371 exhibited increased sensitivity to grow on 7H10 plate supplemented with indicated concentration of moxifloxacin, norfloxacin, ofloxacin and ciprofloxacin (Fig. 2), but its sensitivity to other antibiotics, including isoniazid, rifampicin, spectinomycin, chloramphenicol, capreomycin, remained the same (Fig. S1). To confirm the hypersensitivity of the mutant, MICs of M371 were determined in 7H9 liquid medium at 37 °C supplemented with antimicrobials at indicated concentrations with 2–4 fold increment (Table 1). No MIC difference between wild type M. smegmatis (WT) and M371 was found for ciprofloxacin. One possible interpretation is their difference is minor and less than 2-folds (Table 1). The results confirmed that M371 is hypersensitive to fluoroquinolones. Fatty acids, the major components critical for cell wall permeability, did not show significant difference between the WT and M371 by GC-MS analysis (Fig. S2).
Mutant M371 is an M. smegmatis mc2155 MSMEG_3888 disruptant
To determine the molecular mechanism underlying the intrinsic fluoroquinolones resistance of mycobacteria in M371, plasmid rescue was used to locate and identify the disrupted gene. Results showed that transposon inserted a CA dinucleotide, 137 bp downstream from the ATG start codon of an open reading frame (ORF) of MSMEG_3888, which is predicted to encode a 318-amino acid polypeptide (Fig. 3A). To confirm this, we PCR amplified this gene using M. smegmatis mc2155 and M371 genome as template respectively. Results showed that an additional 2 kb product present in the M371 genome instead of M. smegmatis mc2155 (Fig. 3B). Taken together, the M371 mutant is an MSMEG_3888 transposon insertion. BLAST results showed MSMEG_3888 homologs are ubiquitous among actinomycetes, including M. tuberculosis (69% amino acid identity, pafC), M. marinum M (68%), Nocardia brasiliensis (56%) (Fig. S3). PafC forms an operon with pafB and pafA in Mycobacterium and Corynebacterium. However, this operon was intervened by two genes in Streptomyces and Nocardia (Fig. S4). There is a conserved WYL domain in PafC via query in Conserved Domain Datebase (CDD) of NCBI (Fig. S5).
Complementation of mutant M371
To establish the causality between the hypersensitive phenotype of M371 and mutation of MSMEG_3888, instead of secondary mutation or polar effects on downstream genes, we cloned the M. tuberculosis pafC gene into a shuttle vector pALACE19. The recombinant plasmid pALACE-pafC and empty vector pALACE were transformed into M371 by electroporating to prior obtained recombinant strains. Western Blot analysis using the anti-His antibody further confirmed the presence of the expressed ~40 kDa PafC-His fusion protein in the cell lysates of the complemented strain and absence in the parental strain (Fig. 3C). The recombinant strains M371-pALACE-pafC and M371-pALACE were spotted on Middlebrook 7H10 containing various fluoroquinolones. The results showed that the pafC gene of M. tuberculosis complemented the mutant phenotypes of M371, but M371-pALACE failed to grow (Fig. 2). These results suggested that pafC is the gene underlying the fluoroquinolones intrinsic resistance.
A pafC deficiency can potentiate the fluoroquinolones lethality
The gene of pafC encode a proteasome accessory factor C in mycobacterium, forming an operon with Rv2096c (pafB) and Rv2097c (pafA)18. pafA encoded pup ligase is responsible for pup conjugation to substrates subject to intracellular protein degradation15. PafA is essential for M. tuberculosis survival under RNI exposure in vitro and virulence in vivo20. PafB and pafC was speculated to play a role in RNI resistance18. To determine whether pafC deficiency will compromise the survival during lethal fluoroquinolones stress, we exposed M. smegmatis and M371 cells to fluoroquinolones. When wild-type and pafC-deficient cells were treated with various concentration of moxifloxacin for 2 h (Fig. 4A), survival rate of the pafC mutant was 10 to 20-fold lower than that of wild-type cells. Similar phenomenon was observed when wild-type and pafC mutant were treated with norfloxacin, ofloxacin and ciprofloxacin for 4 h (Fig. 4B–D). The pafC mutation can potentiate the lethal action of fluoroquinolones. Similar survival rates were observed between WT and M371 treated with moxifloxacin even when the concentration of bacteria was increased (Fig. 5). Both rifampicin and isoniazide are first-line anti-TB drugs, the survival of WT and M371 exposure to both drugs was compared. Slight difference was observed when treated with rifampicin, but not with isoniazide (Fig. S6).
pafC is involved in the rapid killing effect of H2O2
A previous study has shown that fluoroquinolones stimulate the production of highly deleterious hydroxyl radicals in Gram-negative and Gram-positive bacteria, which ultimately contribute to cell death21. H2O2 is an important molecule highly reactive and can react with iron to generate hydroxyl radicals from Fenton reaction22. To determine whether the sensitivity of M371 to fluoroquinolones is caused by reactive oxygen species, we examined the effect of pafC deficiency on the lethality of oxidative stress. The survival rates were compared between wild-type and pafC deficient cells using disk diffusion antibiotic sensitivity testing (Fig. 6A). The results showed that M371 was more sensitive than wild-type against stress (Fig. 6B). To further confirm pafC mutant was responsible for the H2O2 sensitivity, wild-type and M371 were exposed to 5 mM H2O2 for various incubation duration. The results showed that M371 survival declined by 10–100 fold, while the wild-type cells remained viable till 1 h after exposure (Fig. 6C). Taken together, these results unequivocally demonstrated that pafC deficiency increases the lethal effect of H2O2.
The addition of thiourea or 2, 2’-bipyridyl can abrogate or attenuate the lethality of moxifloxacin
To further test that hydroxyl radicals contribute to the lethality of moxifloxacin for M371 and wild-type, exponentially growing cells were treated with 2, 2'-bipyridyl (an iron chelator) that interferes with the Fenton reaction and with thiourea, a hydroxyl radical scavenger. Both thiourea and bipyridyl can protect the M371 strain and wild-type cells from moxifloxacin. The same lethality rate was observed between M371 and wild-type at low concentration of moxifloxacin when treated with thiourea or bipyridyl, but less protective to M371 than to wild-type cells at high concentration (Fig. 7). The observed incomplete protection might be due to of the application of subinhibitory concentration of thiourea and bipyridyl that were unable to completely eliminate hydroxyl radical accumulation. Thus, these results suggested that the deficiency of pafC can potentiate the lethality of several fluoroquinolones and might be the result of accumulated hydroxyl radicals.
Discussion
Emerging drug resistant tuberculosis represents formidable challenge to global public health. Intensive studies have unveiled a multitude of mechanisms of action underlying such drug resistance in addition to drug-specific targets, such as efflux pumps23 of MFS family24,25,26,27,28, ABC family29,30,31 and RND Family32. These efflux proteins can mediate broad-spectrum resistance to streptomycin, rifampicin, fluoroquinolones, ethambutol, ethionamide, isoniazid and other compounds. Metabolic and signaling related genes are recently reported to be involved in intrinsic resistance to multiple antituberculosis drugs, such as asparagine synthetase asnB, protein kinase G, isocitrate lyase, a key enzyme of glyoxylate shunt8,33,34,35. These findings enabled more druggable targets for future antibiotics development.
In this study, we identified mycobacteria proteasome accessory factor C (pafC) as a novel gene underlying intrinsic resistance to fluoroquinolones. Fluoroquinolones are important antibiotics for tuberculosis treatment. Wild-type mycobacteria are intrinsic resistant to fluoroquinolones and drug efflux pump30,36,37 or pentapeptide protein MfpA38 are reported to be responsible for this resistance. We demonstrated that inactivation of the pafC gene in M. smegmatis confers hypersensitivity to fluoroquinolones including moxifloxacin, norfloxacin, ofloxacin and ciprofloxacin and M. tuberculosis counterpart can restore the phenotype, indicating that mycobacteria pafC is involved in the intrinsic resistance to fluoroquinolones. To the best of our knowledge, this is the first time that pafC has been reported to be involved in fluoroquinolones intrinsic resistance.
We also found that the effect of pafC on the fluoroquinolones sensitivity is related to reactive oxygen species. Two pathways are proposed to interpret the bacteriocidal effect of the new generation of fluoroquinolones. One is chloramphenicol-sensitive pathway and depend on hydroxyl radical, the other is chloramphenicol-insensitive lethal pathway39. The pafC mutant is more sensitive to H2O2 than wild type M. smegmatis. The protective assay of thiourea and bipyridyl further confirmed that the accumulation of reactive oxygen species played a role in pafC mediated fluoroquinolones sensitivity. The different sensibility of M371 between various fluoroquinolones (Fig. 2) might be associated with the structure or ability to produce reactive oxygen species. The production of reactive oxygen species (ROS) is proposed to be a common mechanism of cellular death induced by bactericidal antibiotics21. Though the idea that antibiotics kill bacterial cells through the action of ROS was challenged by others40,41, it has been supported by a number of follow-up studies42,43,44,45. Recent studies show that lethal attacks from bacterial and viral species also result in ROS production in target cells46. The slight survival rate difference between WT and M371 observed when treated with rifampicin might be due to the formation of hydroxyl radical induced by rifampicin in M. tuberculosis47. However, the mechanism underlying the role of hydroxyl radical in pafC mutant hypersensitive to fluoroquinolones remains to be further illuminated. Three genes, pafA, pafB and pafC, were previously identified to be in an operon and all three genes appear to play a role in RNI resistance18. M. tuberculosis is continually exposed to endogenous reactive oxygen species (ROS) as part of normal aerobic respiration, as well as exogenous ROS and reactive nitrogen species (RNS) generated by the host immune system in response to infection48. Our finding may provide further evidence that pafC enhances mycobacterial survival within macrophages.
The biochemical characteristics of pafC remain elusive. The only anecdotal clue for its biochemical function is the conserved WYL domain in pafC. WYL domain bearing transcription factors are reported to regulate the expression of the defense systems unless a specific ligand is present either to derepress or activate transcription49. Further biochemical characterization of pafC will help elucidate the role of pafC in intrinsic drug resistance. To our knowledge, Compartmentalized proteases are often involved in regulating the stability of transcription factors, directly or indirectly50,51. Notably a recent study showed that defects in proteasome-dependent degradation resulted in transcriptional changes in M. tuberculosis52. Thus, we speculate that the phenomenon we observed as a result of pafC mutant may affect transcription factors and metal homeostasis.
The intrinsic drug resistance of Mycobacterium, in particular the M. tuberculosis, represents formidable obstacle to tuberculosis treatment. The finding that pafC mediating intrinsic resitance to the important fluoroquinolones implicates that novel compounds inhibiting the pafC function might represent ideal potentiators of fluoroquinolones. The limited and conserved distribution of pafC in actinomycetes suggests that such new inhibitors might be narrow spectrum and will not disturb the normal flora.
Methods
Bacterial strains, plasmid and growth conditions
M. smegmatis mc2155 and M371 were grown in Middlebrook 7H9 medium supplemented with 0.05% Tween80 and 0.2% glycerinum or Middlebrook 7H10 plates supplemented with 0.5% glycerinum. Luria-Bertani medium was used to culture E. coli strains. Antibiotic were added at following concentrations: ampicillin, 100 μg/ml; kanamycin, 50 μg/ml for E. coli and 20 μg/ml for M. smegmatis mc2155; hygromycin, 75 μg/ml for E. coli or 50 μg/ml for M. smegmatis mc2155. All cultures were incubated at 37 °C.
Construction and screen of M. smegmatis mc2155 ΦMycoMar insertion library
The transposon system ΦMycoMarT7 was utilized to construct a transposon insertion mutant library of M. smegmatis mc2155 as described previously53,54. For phage infection, M. smegmatis mc2155 cells were grown to late-log phase in Middlebrook 7H9 broth without antibiotics. Cells were pelleted, washed twice with mycobacteriophage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgSO4, 2 mM CaCl2) and then resuspended in the same buffer. Phage was added at a multiplicity of infection of 10:1 and the cells and phage were incubated at 37 °C for 4 h to allow infection to occur. The bacteria were then plated on Middlebrook 7H10 agar supplemented with kanamycin (20 μg/ml) and incubated at 37 °C for 3-4 days. Kanamycin-resistant (i.e., transposon-containing) M. smegmatis colonies were patched onto Middlebrook 7H10 agar to obtain a library of 3500 clones. To screen this library, clones were replica plated onto Middlebrook 7H10 agar supplemented with moxifloxacin at one-third the MIC for the WT M. smegmatis mc2155. Clones that failed to grow on the drug-containing plates were deemed hypersensitive. The MIC was determined to further confirm the drug hypersensitive of obtained clone.
Localization of the ΦMycoMar insertion
Plasmid rescue was used to localize and identify the disrupted gene as previously described53,55. Total chromosomal DNA of transposon insertion mutant was digested with SacII. Digested DNA was self-ligated with T4 DNA ligase and transformed into competent E. coli DH5α cells. Plasmid DNA was isolated from Kmr E. coli DH5α cells. The primer of 5′-GCCTTCTTGACGAGTTCTTCTGAG-3′ was used to determine the DNA sequence of the MycoMar/chromosomal junction. These DNA sequences were compared with the M. smegmatis mc2155 genome. The primers of flanking sequence were designed to further determine the location of transponson.
Cloning the gene of pafC from M. tuberculosis
The gene of pafC from M. tuberculosis H37Rv was amplified by PCR using the forward primer 5′-GAGCCATATGATGAGCGCCCTGT-3′ and reverse primer 5′-TTAATCGATTCACGGCGGCGCAGCT-3′. The target gene was inserted into the NdeI and ClaI of pALACE which contains a hygromycin resistance cassette as described19. The recombinant plasmid was sequenced to confirm the right clone and named pALACE-pafC . Plasmids pALACE-pafC and pALACE were transformed into mycobacterial cells by electroporation according to standard protocol. Transformants were selected on Middlebrook 7H10 agar containing hygromycin (50 μg/ml).
Antimicrobial susceptibility assays
Four methods were used for measuring antibiotic or H2O2 effect.
Spot tests
Wild type M. smegmatis mc2155 and mutant strains were grown to an A600 of 0.8–1.0 tested for their susceptibility to antibiotics by spotting a 10-fold serial dilution initially on Middlebrook 7H10 (Difco) plates containing a range of drug: moxifloxacin (0.04 μg/ml), norfloxacin (1 μg/ml), ofloxacin (0.125 μg/ml), ciprofloxacin (0.08 μg/ml), isoniazid (8 μg/ml), rifampicin (4 μg/ml), spectinomycin (32 μg/ml), chloramphenicol (16 μg/ml), capreomycin (2 μg/ml).
MIC
Growth inhibition (MIC) was determined by broth dilution with visual inspection of a series of tubes each containing about 105 bacteria in 1 ml of 7H9 medium supplemented with concentrations of drug increasing by 2 times increments. Following 3 days incubation at 37 °C, the lowest concentration that prevented visible growth was defined as the MIC.
Disk diffusion method
The disk diffusion method was used to qualitatively measure the differences in H2O2 sensitivities between wild type and mutant mycobacterium. Mid-exponential-phase cultures were used to prepare the lawns of cells as previously described56. An indicated amount of H2O2 was spotted on 5.5 mm-diameter Whatman filter disks placed on the bacterial lawn. After overnight incubation, the diameter of zone of complete inhibition was measured. All the experiment was repeated at least three times.
Survival curves
Mid-exponential phase culture were diluted in 7H9 medium and grown at 37 °C treated for various times and at various concentrations with antibiotics and surviving cells were estimated by colony formation on drug-free agar. The percentage cfu recovered was determined relative to an untreated control sampled at the time when antibiotics added. The effect of hydroxyl radicals on fluoroquinolones-mediated lethality was assessed by treating cells with subinhibitory concentration of 2,2'-bipyridyl and thiourea were added to bacterial cultures, followed by fluoroquinolones treatment for indicated times and at indicated concentrations. All the CFU data are listed in the supplementary materials.
Additional Information
How to cite this article: Li, Q. et al. Proteasome Accessory Factor C (pafC) Is a novel gene Involved in Mycobacterium Intrinsic Resistance to broad-spectrum antibiotics - Fluoroquinolones. Sci. Rep. 5, 11910; doi: 10.1038/srep11910 (2015).
References
Organization WH. Global tuberculosis report 2013. World Health Organization (2013).
Ginsberg, A. M. & Spigelman, M. Challenges in tuberculosis drug research and development. Nature 13, 290–294 (2007).
Wright, A. et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. The Lancet 373, 1861–1873 (2009).
Zignol, M. et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bulletin of the world Health Organization 90, 111–119 (2012).
Jarlier, V. & Nikaido, H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 123, 11–18 (1994).
Silver, L. L. Challenges of antibacterial discovery. Clinical microbiology reviews 24, 71–109 (2011).
da Silva, P. E. A., Von Groll, A., Martin, A. & Palomino, J. C. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunology & Medical Microbiology 63, 1–9 (2011).
Ren, H. & Liu, J. AsnB is involved in natural resistance of Mycobacterium smegmatis to multiple drugs. Antimicrobial agents and chemotherapy 50, 250–255 (2006).
Velayutham, B. V. et al. Sputum Culture Conversion With Moxifloxacin-Containing Regimens in the Treatment of Patients With Newly Diagnosed Sputum-Positive Pulmonary Tuberculosis in South India. Clinical Infectious Diseases, ciu550 (2014).
Shim, T. S. & Jo, K.-W. Medical treatment of pulmonary multidrug-resistant tuberculosis. Infection & chemotherapy 45, 367–374 (2013).
Seung, K. et al. Salvage therapy for multidrug - resistant tuberculosis. Clinical Microbiology and Infection 20, 441–446 (2014).
Ginsburg, A. S., Grosset, J. H. & Bishai, W. R. Fluoroquinolones, tuberculosis and resistance. The Lancet infectious diseases 3, 432–442 (2003).
Drlica, K. & Zhao, X. DNA gyrase, topoisomerase IV and the 4-quinolones. Microbiology and molecular biology reviews 61, 377–392 (1997).
Maruri, F. et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. Journal of Antimicrobial Chemotherapy 67, 819–831 (2012).
Pearce, M. J., Mintseris, J., Ferreyra, J., Gygi, S. P. & Darwin, K. H. Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis. Science 322, 1104–1107 (2008).
Elharar, Y. et al. Survival of mycobacteria depends on proteasome‐mediated amino acid recycling under nutrient limitation. The EMBO journal 33, 1802–1814 (2014).
Lin, G. et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature 461, 621–626 (2009).
Festa, R. A., Pearce, M. J. & Darwin, K. H. Characterization of the proteasome accessory factor (paf) operon in Mycobacterium tuberculosis. Journal of bacteriology 189, 3044–3050 (2007).
Rawat, M., Kovacevic, S., Billman-Jacobe, H. & Av-Gay, Y. Inactivation of mshB, a key gene in the mycothiol biosynthesis pathway in Mycobacterium smegmatis. Microbiology 149, 1341–1349 (2003).
Darwin, K. H., Ehrt, S., Gutierrez-Ramos, J.-C., Weich, N. & Nathan, C. F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302, 1963–1966 (2003).
Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collins, J. J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797–810 (2007).
Winterbourn, C. C. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicology letters 82, 969–974 (1995).
Ryan, B. M. et al. Efflux in bacteria: what do we really know about it? Expert opinion on investigational drugs 10, 1409–1422 (2001).
Jiang, X. et al. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microbial drug resistance 14, 7–11 (2008).
Silva, P. E. et al. Characterization of P55, a Multidrug Efflux Pump inMycobacterium bovis and Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 45, 800–804 (2001).
De Rossi, E. et al. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Molecular medicine 8, 714 (2002).
Gupta, A. K. et al. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microbial drug resistance 16, 21–28 (2010).
Wilson, M. et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proceedings of the National Academy of Sciences 96, 12833–12838 (1999).
Choudhuri, B. et al. Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J 367, 279–285 (2002).
Pasca, M. R. et al. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 48, 3175–3178 (2004).
Danilchanka, O., Mailaender, C. & Niederweis, M. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 52, 2503–2511 (2008).
Pasca, M. R., Guglierame, P., De Rossi, E., Zara, F. & Riccardi, G. mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrobial agents and chemotherapy 49, 4775–4777 (2005).
Wolff, K. A. et al. Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria. Antimicrobial agents and chemotherapy 53, 3515–3519 (2009).
Bowman, J. & Ghosh, P. A complex regulatory network controlling intrinsic multidrug resistance in Mycobacterium smegmatis. Molecular microbiology 91, 121–134 (2014).
Nandakumar, M., Nathan, C. & Rhee, K. Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis. Nature communications 5, 4306–4306 (2013).
Liu, J., Takiff, H. E. & Nikaido, H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. Journal of bacteriology 178, 3791–3795 (1996).
Takiff, H. et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proceedings of the National Academy of Sciences 93, 362–366 (1996).
Montero, C., Mateu, G., Rodriguez, R. & Takiff, H. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrobial agents and chemotherapy 45, 3387–3392 (2001).
Wang, X., Zhao, X., Malik, M. & Drlica, K. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. Journal of Antimicrobial Chemotherapy 65, 520–524 (2010).
Liu, Y. & Imlay, J. A. Cell death from antibiotics without the involvement of reactive oxygen species. Science 339, 1210–1213 (2013).
Keren, I., Wu, Y., Inocencio, J., Mulcahy, L. R. & Lewis, K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339, 1213–1216 (2013).
Dwyer, D. J., Collins, J. J. & Walker, G. C. Unraveling the physiological complexities of antibiotic lethality. Annual review of pharmacology and toxicology 55, 313–332 (2015).
Davies, B. W. et al. Hydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli. Molecular cell 36, 845–860 (2009).
Wang, X. & Zhao, X. Contribution of oxidative damage to antimicrobial lethality. Antimicrobial agents and chemotherapy 53, 1395–1402 (2009).
Yeom, J., Imlay, J. A. & Park, W. Iron homeostasis affects antibiotic-mediated cell death in Pseudomonas species. Journal of Biological Chemistry 285, 22689–22695 (2010).
Dong, T. G. et al. Generation of reactive oxygen species by lethal attacks from competing microbes. Proceedings of the National Academy of Sciences 112, 2181–2186 (2015).
Piccaro, G., Pietraforte, D., Giannoni, F., Mustazzolu, A. & Fattorini, L. Rifampin Induces Hydroxyl Radical Formation in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 58, 7527–7533 (2014).
Kumar, A. et al. Redox homeostasis in mycobacteria: the key to tuberculosis control? Expert reviews in molecular medicine 13, e39 (2011).
Makarova, K., Anantharaman, V., Grishin, N., Koonin, E. & Aravind, L. CARF and WYL domains: ligand-binding regulators of prokaryotic defense systems. Frontiers in genetics 5, 102 (2014).
Gottesman, S. Proteolysis in Bacterial Regulatory Circuits1 1. Annual review of cell and developmental biology 19, 565–587 (2003).
Collins, G. A. & Tansey, W. P. The proteasome: a utility tool for transcription? Current opinion in genetics & development 16, 197–202 (2006).
Festa, R. A. et al. A novel copper - responsive regulon in Mycobacterium tuberculosis. Molecular microbiology 79, 133–148 (2011).
Long, Q. et al. Involvement of Holliday junction resolvase in fluoroquinolone-mediated killing of Mycobacterium smegmatis. Antimicrobial agents and chemotherapy, AAC. 04434-04414 (2014).
Murry, J., Sassetti, C., Lane, J., Xie, Z. & Rubin, E. Transposon site hybridization in Mycobacterium tuberculosis. Methods in molecular biology (Clifton, NJ) 416, 45 (2008).
Siegrist, M. & Rubin, E. Phage transposon mutagenesis. Methods in molecular biology (Clifton, NJ) 465, 311–323 (2008).
Bauer, A., Kirby, W., Sherris, J. C. & turck, Turck, M. Antibiotic susceptibility testing by a standardized single disk method. American journal of clinical pathology 45, 493 (1966).
Acknowledgements
This work was supported by National Natural Science Foundation [grant numbers 81371851, 81071316, 81271882, 81301394], New Century Excellent Talents in Universities [grant number NCET-11-0703], National Megaprojects for Key Infectious Diseases [grant numbers 2008ZX10003-006], Excellent Ph.D. thesis fellowship of Southwest University [grant numbers kb2010017, ky2011003], the Fundamental Research Funds for the Central Universities [grant numbers XDJK2011D006, XDJK2012D011, XDJK2012D007, XDJK2013D003, XDJK2014D040], Graduate research and innovation project of graduate in Chongqing (CYS14044), The Chongqing Municipal Committee of Education for postgraduates excellence program [grant numbers YJG123104] and The undergraduates teaching reform program [grant numbers 2013JY201].
Author information
Authors and Affiliations
Contributions
Q.M.L., L.X., Q.X.L., J.M., H.L. and M.Z. performed the experiments. Q.M.L. and L.X. analyzed the data. J.X. contributed with reagents and materials. Q.M.L. and J.X. designed the study and wrote the paper.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Electronic supplementary material
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Li, Q., Xie, L., Long, Q. et al. Proteasome Accessory Factor C (pafC) Is a novel gene Involved in Mycobacterium Intrinsic Resistance to broad-spectrum antibiotics - Fluoroquinolones. Sci Rep 5, 11910 (2015). https://doi.org/10.1038/srep11910
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep11910
This article is cited by
-
Mycobacterium smegmatis PafBC is involved in regulation of DNA damage response
Scientific Reports (2017)
-
Mycobacteriophage SWU1 gp39 can potentiate multiple antibiotics against Mycobacterium via altering the cell wall permeability
Scientific Reports (2016)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.